高级检索
陆咨儒, 谢林, 相萍萍, 梁宇, 严亮, 梁爱军. 辛伐他汀治疗酒精性股骨头坏死的效果及机制初步探讨[J]. 实用临床医药杂志, 2021, 25(8): 96-100. DOI: 10.7619/jcmp.20201978
引用本文: 陆咨儒, 谢林, 相萍萍, 梁宇, 严亮, 梁爱军. 辛伐他汀治疗酒精性股骨头坏死的效果及机制初步探讨[J]. 实用临床医药杂志, 2021, 25(8): 96-100. DOI: 10.7619/jcmp.20201978
shu
LU Ziru, XIE Lin, XIANG Pingping, LIANG Yu, YAN Liang, LIANG Aijun. Effect of simvastatin in treatment of alcoholic osteonecrosis of femoral head and preliminary exploration of mechanism[J]. Journal of Clinical Medicine in Practice, 2021, 25(8): 96-100. DOI: 10.7619/jcmp.20201978
Citation: LU Ziru, XIE Lin, XIANG Pingping, LIANG Yu, YAN Liang, LIANG Aijun. Effect of simvastatin in treatment of alcoholic osteonecrosis of femoral head and preliminary exploration of mechanism[J]. Journal of Clinical Medicine in Practice, 2021, 25(8): 96-100. DOI: 10.7619/jcmp.20201978
shu

辛伐他汀治疗酒精性股骨头坏死的效果及机制初步探讨

Effect of simvastatin in treatment of alcoholic osteonecrosis of femoral head and preliminary exploration of mechanism

    摘要
  • 摘要:
      目的  观察辛伐他汀联合阿仑膦酸钠对酒精性股骨头坏死（AIANFH）的疗效及对Toll样受体4（TLR4）/核因子κB（NF-κB）通路的影响。
      方法  将90例AIANFH患者随机分为观察组和对照组，每组45例。对照组采用阿仑膦酸钠口服治疗，观察组在对照组基础上联合应用辛伐他汀治疗，疗程均为3个月。比较2组治疗后髋关节优良率和不良反应发生情况，并比较2组治疗前后血清肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）、脂联素、骨钙素水平和外周血单个核细胞（PBMC）的TLR4 mRNA、NF-κB p65 mRNA表达差异。
      结果  治疗后，观察组髋关节优良率91.11%高于对照组的75.56%，差异有统计学意义（P < 0.05）。2组治疗后的血清TNF-α、IL-1β、IL-6水平低于治疗前，血清脂联素、骨钙素水平高于治疗前，差异有统计学意义（P < 0.05）；观察组治疗后的血清TNF-α、IL-1β、IL-6水平低于对照组，血清脂联素、骨钙素水平高于对照组，差异有统计学意义（P < 0.05）。治疗后，2组PBMC的TLR4 mRNA、NF-κB p65 mRNA表达均低于治疗前，且观察组低于对照组，差异有统计学意义（P < 0.05）。观察组和对照组不良反应总发生率分别为24.44%和15.56%，差异无统计学意义（P>0.05）。
      结论  辛伐他汀联合阿仑膦酸钠治疗AIANFH可抑制TLR4/NF-κB信号通路，抑制炎症反应，上调脂联素和骨钙素水平，且安全性高。

     

    Abstract:
      Objective  To observe the effect of simvastatin combined with alendronate sodium in treating alcohol-induced avascular necrosis of femoral head (AIANFH) and its impact on toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB) pathway.
      Methods  A total of 90 patients with AIANFH were selected and divided into observation group and control group, with 45 cases in each group. The control group was treated with alendronate sodium orally, and the observation group was addtionally given simvastatin. The course of treatment was 3 months. The excellent rate of hip joints and incidence of adverse reactions after treatment of two groups were compared, and serum levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), adiponectin, osteocalcin and the mRNA expressions of TLR4 and NF-κB p65 in peripheralblood mononuclear cells (PBMC) were compared between the two groups before and after treatment.
      Results  The excellent rate of hip joints in observation group was higher than that in the control group (91.11% versus 75.56%, P < 0.05). After treatment, serum TNF-α, IL-1β, and IL-6 levels of two groups were significantly lower than treatment before, and serum adiponectin and osteocalcin were increased (P < 0.05). After treatment, expressions of TLR4 mRNA and NF-κB p65 mRNA of PBMC in two groups were decreased, and the were lower in the observation group than those in the control group (P < 0.05). The total incidence of adverse reactions in the observation group and the control group were 24.44% and 15.56%, but no differences were found(P>0.05).
      Conclusion  Simvastatin combined with alendronate sodium can inhibit the TLR4/NF-κB signaling pathway, inhibit inflammation, and up-regulate the levels of adiponectin and osteocalcin, and it has higher safety.

     

    • HTML全文
    • 参考文献(20)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回